WILMINGTON, MA--(Marketwire - Apr 3, 2012) - Implant Sciences Corporation (OTCQB: [ IMSC ]) (PINKSHEETS: [ IMSC ]), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has hired Andrew Anderson as its Director of Engineering, reporting to Todd Silvestri, Vice President of Technology. Mr. Anderson brings a wealth of experience in security and detection to Implant Sciences. This announcement follows on the heels of Implant Sciences appointing explosives trace detection industry pioneer, Dr. Bill McGann, as its Chief Operating Officer. These appointments are made to support current and near term anticipated growth.

Mr. Anderson was most recently Director of Engineering at L-3 Communications Security and Detection Systems, where he directed a team responsible for development of x-ray security inspection equipment used for checkpoints and air cargo applications. Before joining L-3, he was Product Development Manager / Programs Manager at Sionex Corporation, where he developed and produced trace gas chemical detection systems for the defense, security, and life science markets. Mr. Anderson has an MS in Manufacturing Engineering and a BS in Mechanical Engineering, both from the University of Massachusetts.

"This is an exciting opportunity to join a high-caliber team that is prepared to tackle any challenge," stated Andy Anderson, Implant Sciences' new Director of Engineering. "Implant Sciences is on the runway and ready for takeoff. The Company's innovative technologies address the customer needs of today with a roadmap well into the future."

Implant Sciences President and CEO Glenn D. Bolduc commented, "We believe our continued ability to attract top talent for both executive and management-level positions speaks to the value of our products in the marketplace as well as the culture of innovation and growth we have fostered here at Implant Sciences. We welcome Andy to our team. He will work closely with Todd Silvestri and Bill McGann to advance our technologies, products, and manufacturing processes."

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at [ www.implantsciences.com ]

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.